Blacks’ Breast Cancer Treatment Lacking
African-American Women Less Likely to Get Supplemental Breast Cancer Treatment
WebMD News Archive
Oct. 8, 2007 -- African-American women may miss out on potentially
lifesaving supplemental treatments for breast cancer that may prevent the
cancer from returning.
A new study shows white women with more advanced breast cancer were more
than four times more likely to take the breast cancer drug tamoxifen and three
times more likely to receive chemotherapy than African-American women. These
supplemental therapies are recommended after breast cancer surgery to kill any
cancer cells that the surgery may have missed.
"We have seen that African-American women are not getting the optimal
therapy as often as white Americans," says researcher Mousumi Banerjee,
PhD, of the University of Michigan, in a news release. “Some of it has to do
with socioeconomics, some with insurance status and/or access to care, but
there are choice issues as well, especially with chemotherapy."
African-American women are more likely to die of breast cancer than white
women. Researchers say this and other recent studies suggest that the reason
why may be due to a combination of factors. For example, African-American women
are more likely to be diagnosed at a later stage of the disease.
The Role of Race
In the study, published in the journal Cancer, researchers looked at
the role of race and other demographic factors in the treatment of 651 women
diagnosed with breast cancer in Detroit in the early to mid-1990s.
Among those whose breast cancer had not spread to surrounding tissues, the
results showed no significant differences in treatment received, such as the
number of white and African-American women who received breast conservation
surgery vs. mastectomy.
But among women whose cancer had spread to the lymph nodes or surrounding
tissue, white women were more than four times more likely to receive the widely
used breast cancer drug tamoxifen than African-American women. In addition,
African-American women were three times less likely to receive chemotherapy as
a supplemental breast cancer treatment.
Researchers say the results suggest that culturally sensitive ways to
increase use of supplemental breast cancer treatments may be needed to improve
the treatment of African-American women with breast cancer.